- Home
- KOSS vs CGTX Comparison
KOSS vs CGTX Comparison
Compare KOSS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- CGTX
- Stock Information
- Founded
- KOSS 1953
- CGTX 2007
- Country
- KOSS United States
- CGTX United States
- Employees
- KOSS N/A
- CGTX N/A
- Industry
- KOSS Consumer Electronics/Appliances
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- KOSS Consumer Staples
- CGTX Health Care
- Exchange
- KOSS Nasdaq
- CGTX Nasdaq
- Market Cap
- KOSS 63.0M
- CGTX 79.3M
- IPO Year
- KOSS N/A
- CGTX 2021
- Fundamental
- Price
- KOSS $7.34
- CGTX $0.55
- Analyst Decision
- KOSS
- CGTX Buy
- Analyst Count
- KOSS 0
- CGTX 6
- Target Price
- KOSS N/A
- CGTX $8.00
- AVG Volume (30 Days)
- KOSS 183.8K
- CGTX 588.8K
- Earning Date
- KOSS 11-08-2024
- CGTX 11-08-2024
- Dividend Yield
- KOSS N/A
- CGTX N/A
- EPS Growth
- KOSS N/A
- CGTX N/A
- EPS
- KOSS N/A
- CGTX N/A
- Revenue
- KOSS $12,265,069.00
- CGTX N/A
- Revenue This Year
- KOSS N/A
- CGTX N/A
- Revenue Next Year
- KOSS N/A
- CGTX N/A
- P/E Ratio
- KOSS N/A
- CGTX N/A
- Revenue Growth
- KOSS N/A
- CGTX N/A
- 52 Week Low
- KOSS $2.27
- CGTX $0.34
- 52 Week High
- KOSS $18.73
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- KOSS 50.17
- CGTX 54.28
- Support Level
- KOSS $7.00
- CGTX $0.50
- Resistance Level
- KOSS $7.83
- CGTX $0.64
- Average True Range (ATR)
- KOSS 0.44
- CGTX 0.07
- MACD
- KOSS -0.01
- CGTX 0.02
- Stochastic Oscillator
- KOSS 32.26
- CGTX 67.74
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-cancelling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.